[Therapy of asthma: anti-inflammatory effects of antileukotrienes].
The antileukotrienes (anti-LT), consisting of synthesis inhibitors and leukotriene receptor antagonists, represent a new direction in targeted drug therapy for asthma. In the present article, the anti-inflammatory properties of anti-LT are briefly summarized. Orally administered anti-LT inhibit the allergen-induced early and late asthmatic reactions and may attenuate the allergen-associated hyperresponsiveness. They also have a remarkable inhaled steroid-sparing effect. In chronic asthma, anti-LT may exert significant therapeutic benefit. In addition to their properties as relievers, anti-LT may have properties as controllers of asthma.
Ukena
D
D
Medizinische Universitätsklinik, Innere Medizin V, Homburg.
D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D016535:Bronchial Hyperreactivity / Q000188:drug therapy; D001985:Bronchial Provocation Tests; D018849:Controlled Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000187:drug effects; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D008134:Long-Term Care; D010366:Peak Expiratory Flow Rate / Q000187:drug effects
D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D005938:Glucocorticoids; D020024:Leukotriene Antagonists